2023 World Conference on Lung Cancer (Posters)-EP10.01. Predictors of Survival for Docetaxel as a Subsequent Line after Progression to Platinum-Based Chemotherapy and Immunotherapy

EP10.01. Predictors of Survival for Docetaxel as a Subsequent Line after Progression to Platinum-Based Chemotherapy and Immunotherapy - PDF(Abstract)

Back to course

Pdf Summary

This study evaluated the efficacy of docetaxel as a subsequent line of treatment for patients with metastatic non-small cell lung cancer (NSCLC) who had previously progressed on platinum-based chemotherapy and anti PD1/PD-L1 inhibitors. The aim was to assess the real-world efficacy of docetaxel in this scenario, as previous clinical trials did not include patients who had received checkpoint inhibitors prior to docetaxel treatment.<br /><br />The study included 65 patients with a median age of 67 years, with the majority being male (67.7%). Most patients had adenocarcinoma (63.1%), followed by squamous cell carcinoma (24.6%), and other histologies (12.3%). The objective response rate for docetaxel was 21.0%, with a control disease rate of 42.1%. However, 55.7% of patients experienced treatment-related toxicity.<br /><br />The median progression-free survival (PFS) was 2.0 months, and the median overall survival (OS) was 6.0 months. A subset of patients (24.6%) were long-term survivors. The analysis showed that histology, presence of hepatic metastases, limited thoracic disease, and extra-thoracic metastatic disease were associated with poor survival in univariate analysis. However, in multivariate analysis, only the presence of hepatic metastases was significantly associated with poor survival.<br /><br />Based on these results, the study concludes that docetaxel had poor survival outcomes in this patient population, emphasizing the need for developing new therapies for patients with NSCLC who have progressed on platinum-based chemotherapy and anti PD1/PD-L1 inhibitors. It suggests that hepatic metastases may be a negative prognostic factor in this context. Further research is needed to identify more effective treatment options for these patients.

Asset Subtitle

Virginia Calvo de Juan

Meta Tag

Speaker Virginia Calvo de Juan

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

docetaxel

metastatic non-small cell lung cancer

platinum-based chemotherapy

anti PD1/PD-L1 inhibitors

real-world efficacy

clinical trials

objective response rate

treatment-related toxicity

progression-free survival

overall survival